AIF1, allograft inflammatory factor 1, 199

N. diseases: 166; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype BEFREE We assessed hyperalgesia, histopathological changes, immunoreactive (-ir) neurons for calcitonin gene-related peptide and activating transcription factor 3 in DRG, and immunoreactive neurons for ionized-calcium-binding adaptor molecule 1 (Iba1) in the dorsal horn of the spinal cord. 31538672 2020
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype BEFREE Results revealed that increased hyperalgesia was concurrent with an increment of Iba1 (P < 0.001), TNF-α (P < 0.001), PTEN (P < 0.01), cleaved caspase-3 (P < 0.001), and a decrement of P.Akt (P < 0.01) during the acute phase of CFA-induced inflammation, while, at the same time as decreasing hyperalgesia during the chronic phase of study, Iba1 and TNF-α expression significantly decreased and PTEN, cleaved caspase-3, and P.Akt restored to baseline on day 0. 31388881 2020
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype BEFREE Behavioral tests revealed allodynia, ongoing pain, and increased expression of c-fos, GFAP, and Iba1, as well as the absence of hyperalgesia in Burn7s. 28181986 2018
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype BEFREE Immunohistochemical analysis showed that spinal microglia were activated and that the P2X4R level was increased and colocalized with ionized calcium-binding adapter molecule 1 in NTW-induced hyperalgesia. 28306606 2017
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.540 Biomarker phenotype RGD Involvement of microglia in the ethanol-induced neuropathic pain-like state in the rat. 17284346 2007
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 AlteredExpression phenotype BEFREE These results suggest that a single injection of duloxetine suppressed mechanical hyperalgesia and may influence the expression of Iba1 in the microglia of the ipsilateral dorsal horn in the MIA-induced hip OA. 31538672 2020
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 AlteredExpression phenotype BEFREE Cutaneous and muscle inflammation induced no change in Iba-1 expression in the dorsal horn.In spite of a marked time-dependent variation in protein expression, mechanical allodynia was present at any time of all the models investigated. 31002029 2019
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 AlteredExpression phenotype BEFREE Intrathecal MaR1 significantly attenuated mechanical allodynia and thermal hyperalgesia from day 5 to day 7 post-SNL, which was associated with decreased spinal levels of glial markers, GFAP and IBA1. 30127635 2018
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 Biomarker phenotype BEFREE We found that not only the ionized calcium-binding adapter molecule 1 (Iba-1)-positive microglia in the ipsilateral spinal cord but also mechanical allodynia was significantly inhibited. 28243146 2017
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 Biomarker phenotype BEFREE The results showed that SNI produced mechanical allodynia and depressive-like behaviors, and also increased the expressions of microglia markers (Iba1, CD11b) and M1 markers (CD68, iNOS, IL-1β, TNF-α, and 8-OH-dG) in the prefrontal cortex. 28458629 2017
CUI: C2936719
Disease: Mechanical Allodynia
Mechanical Allodynia 		0.350 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.340 AlteredExpression disease BEFREE GA treatment effectively reversed clinical (motor dysfunction) and pathology (TH, IBA1, BDNF expression) of PD in a murine model. 31220543 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.340 Biomarker disease BEFREE While many transcripts are already established as those related to PD (alpha-synuclein, caspases, leucine rich repeat kinase 2, and parkin2), lesser studied targets have emerged as "pesticide/PD-associated transcripts" [e.g., phosphatidylinositol glycan anchor biosynthesis class C (Pigc), allograft inflammatory factor 1 (Aif1), TIMP metallopeptidase inhibitor 3, and DNA damage inducible transcript 4]. 30740124 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.340 AlteredExpression disease BEFREE To assess whether inflammation and microglial activation accompany the onset and the progression of PD-like pathology, we investigated the expression of cytokines (<i>interleukin 1 beta (Il1b), interleukin 6 (Il6)</i>) and microglial/macrophage activation markers (<i>Fc gamma receptor III (Fcgr3), mannose receptor 1 (Mrc1), chitinase-like 3 (Ym1), arginase 1 (Arg 1), triggering receptor expressed on myeloid cells 2 (Trem2)</i>), together with microglial ionized calcium binding adapter molecule 1 (Iba1) and astrocyte glial fibrillary acidic protein (GFAP) immunolabeling, in the substantia nigra (SN) of c-rel<sup>-/-</sup> mice, at premotor (4- and 13-month-old) and motor phases (18-month-old). 28769786 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.340 Biomarker disease BEFREE To determine microglia proliferation and activation we analyzed ionized calcium binding adaptor molecule 1 (Iba1) expressing microglia in the glomerular and granular cell layer, and the olfactory tract of the OB from patients with AD, PD dementia/dementia with Lewy bodies (PDD/DLB), and FTLD compared to age-matched controls. 28409032 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease 		0.340 Biomarker disease CTD_human Brain insulin-like growth factor and neurotrophin resistance in Parkinson's disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. 19276553 2009
CUI: C0040997
Disease: Trigeminal Neuralgia
Trigeminal Neuralgia 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0393786
Disease: Trigeminal Neuralgia, Idiopathic
Trigeminal Neuralgia, Idiopathic 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0393787
Disease: Secondary Trigeminal Neuralgia
Secondary Trigeminal Neuralgia 		0.300 Biomarker disease CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0458247
Disease: Allodynia
Allodynia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751211
Disease: Hyperalgesia, Primary
Hyperalgesia, Primary 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751212
Disease: Hyperalgesia, Secondary
Hyperalgesia, Secondary 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751213
Disease: Tactile Allodynia
Tactile Allodynia 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016
CUI: C0751214
Disease: Hyperalgesia, Thermal
Hyperalgesia, Thermal 		0.300 Biomarker phenotype CTD_human Resveratrol suppresses glial activation and alleviates trigeminal neuralgia via activation of AMPK. 27093858 2016